A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachters, F M, Groen, H J M, Biesma, B, Schramel, F M N H, Postmus, P E, Stigt, J A, Smit, E F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361740/
https://www.ncbi.nlm.nih.gov/pubmed/15597104
http://dx.doi.org/10.1038/sj.bjc.6602268
_version_ 1782153288148320256
author Wachters, F M
Groen, H J M
Biesma, B
Schramel, F M N H
Postmus, P E
Stigt, J A
Smit, E F
author_facet Wachters, F M
Groen, H J M
Biesma, B
Schramel, F M N H
Postmus, P E
Stigt, J A
Smit, E F
author_sort Wachters, F M
collection PubMed
description Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.
format Text
id pubmed-2361740
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23617402009-09-10 A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment Wachters, F M Groen, H J M Biesma, B Schramel, F M N H Postmus, P E Stigt, J A Smit, E F Br J Cancer Short Communication Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity. Nature Publishing Group 2005-01-17 2004-12-14 /pmc/articles/PMC2361740/ /pubmed/15597104 http://dx.doi.org/10.1038/sj.bjc.6602268 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Wachters, F M
Groen, H J M
Biesma, B
Schramel, F M N H
Postmus, P E
Stigt, J A
Smit, E F
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title_full A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title_fullStr A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title_full_unstemmed A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title_short A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
title_sort randomised phase ii trial of docetaxel vs docetaxel and irinotecan in patients with stage iiib–iv non-small-cell lung cancer who failed first-line treatment
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361740/
https://www.ncbi.nlm.nih.gov/pubmed/15597104
http://dx.doi.org/10.1038/sj.bjc.6602268
work_keys_str_mv AT wachtersfm arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT groenhjm arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT biesmab arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT schramelfmnh arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT postmuspe arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT stigtja arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT smitef arandomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT wachtersfm randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT groenhjm randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT biesmab randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT schramelfmnh randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT postmuspe randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT stigtja randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment
AT smitef randomisedphaseiitrialofdocetaxelvsdocetaxelandirinotecaninpatientswithstageiiibivnonsmallcelllungcancerwhofailedfirstlinetreatment

Ejemplares similares